The MUC16 mucin is overexpressed and aberrantly glycosylated in ovarian carcinomas. Immunodetection of circulating MUC16 is one of the most used cancer biomarker assays, but existing antibodies to MUC16 fail to distinguish normal and aberrant cancer glycoforms. Although all antibodies react with the tandem-repeat region, their epitopes appear to be conformational dependent and not definable by a short peptide. Aberrant glycoforms of MUC16 may constitute promising targets for diagnostic and immunotherapeutic intervention, and it is important to develop well-defined immunogens for induction of potent MUC16 immunity. Here, we developed a MUC16 vaccine based on a 1.7TR (264 aa) expressed in Escherichia coli and in vitro enzymatically glycosylated to generate the aberrant cancer-associated glycoform Tn. This vaccine elicited a potent serum IgG response in mice and we identified two major immunodominant linear peptide epitopes within the tandem repeat. We developed one monoclonal antibody, 5E11, reactive with a minimum epitope with the sequence FNTTER. This sequence contains potential N-and O-glycosylation sites and, interestingly, glycosylation blocked binding of 5E11. In immunochemistry of ovarian benign and cancer lesions, 5E11 showed similar reactivity as traditional MUC16 antibodies, suggesting that the epitope is not efficiently glycosylated. The study provides a vaccine design and immunodominant MUC16 TR epitopes.
Introduction
MUC16 is a membrane-bound mucin highly expressed in ovarian cancer at protein and mRNA levels, but not expressed in normal ovary (Bast et al. 1981; Kabawat et al. 1983; Bouanene et al. 2011) . The extracellular domain of MUC16 is shed into circulation in ovarian cancer and detected with CA125 immunoassay, one of the most used cancer serum assays . Extracellular MUC16 contains two domains: an N-terminal of ≈12,000 amino acids (aa) without apparent structure but high density of O-glycosylation; a C-terminal containing 60 tandem repeats (TRs) of about 156 aa with a 125 residue SEA (Sperm protein, Enterokinase, Agrin) domain, including on average 3 N-glycans, and a linker-region of 20-30 residues with high density of O-glycosylation (Hattrup and Gendler 2008; Marcos-Silva et al. 2014) .
Previously, monoclonal antibodies (mAbs) produced to MUC16 used MUC16-expressing cancer cells as immunogens Lloyd et al. 1997) . These mAbs react with epitopes in the MUC16 TR and were classified in three clusters with different noncompeting specificities (Nustad et al. 1996) . Recently, we and others have defined their epitopes as a conformational structure within the repeats, not mimicked by a simple peptide sequence (Bressan et al. 2013; Marcos-Silva et al. 2014) . We also demonstrated that N-and O-glycosylation of the TR does not influence their binding (MarcosSilva et al. 2014) .
O-glycosylation is altered in cancer cells usually with accumulation of immature O-glycans, including Tn (GalNAcα1-O-Ser/Thr), STn (Neu5Acα2-6GalNAcα1-O-Ser/Thr) and T (Galβ1-3GalNAcα1-OSer/Thr). These are considered pancarcinoma antigens (Springer 1984) , and the Tn/STn structures are widely expressed in ovarian cancer but not in normal tissue (Inoue et al. 1991) . We recently showed circulating STn-MUC16 in ovarian cancer patients and its selective detection using an antibody-capture microarray strategy improved assay specificity (Chen et al. 2013) . Later, we confirmed this showing that MUC16 carries aberrant O-glycans in ovarian cancer tissue, reinforcing the cancer specificity of Tn/STn-MUC16 glycoforms (Ricardo et al. 2014) .
Previously, we generated mAbs that specifically react with aberrant MUC1 O-glycoforms, which is highly overexpressed in several cancers, including ovarian (Sorensen et al. 2006; Tarp et al. 2007; Chen et al. 2013) . MUC1 is a membrane-bound mucin, shed into circulation and detectable by the serum assay CA15-3 (Gang et al. 1985; Colomer et al. 1986 ). These mAbs that specifically react with aberrant MUC1-glycoforms recognize a combined glycopeptide epitope, including the Tn glycan and a short sequence motif around the glycosite in the TR (Sorensen et al. 2006; Tarp et al. 2007 ). Such antibodies can have high affinity and exhibit remarkable cancer-specific reactivity ).
Here, we developed an MUC16 TR vaccine construct with aberrant O-glycans to probe immunogenicity and explore the possibility of generating glycoform-specific mAbs. We expressed a 1.7TR construct in Escherichia coli and used a polypeptide GalNAc-transferase (GalNAc-T) to introduce ∼15-20 Tn glycans. Mice were immunized with Tn-1.7TR MUC16 protein and analysis of total serum IgG revealed induction of potent IgG response to two distinct peptide regions in the TR. We were unsuccessful in obtaining mAbs with selective reactivity with Tn-MUC16. However, we generated mAb 5E11 that mimicked the reactivity of total serum IgG with the most prevalent peptide immunoepitope in the TR. The 5E11 binding epitope was defined to the FNTTER sequence motif potentially containing N-and O-glycosylation. Interestingly, either type of glycosylation blocked binding, but 5E11 reacted with frozen and paraffin-embedded sections of ovarian cancer tissues and benign ovarian lesions comparatively to traditional anti-CA125 mAbs. mAb 5E11 did not react with the ovarian cancer cell line OVCAR3 or with MUC16 1.2TR construct expressed in Chinese Hamster Ovary (CHO) cells. Interestingly, processing cell pellets as formalin-fixed tissues with HistoGel plus paraffin and antigen retrieval could induce some 5E11 reactivity with these cell lines. Further studies are needed to decipher the mechanism for the differential expression of mAb 5E11 epitope in ovarian tissues, but to our knowledge, this mAb is the first that has a clearly defined binding epitope in the MUC16 TR.
Results
Design and production of a Tn-MUC16 vaccine construct A recombinant MUC16 1.7TR fragment containing one complete SEA domain, N-and C-terminal mucin-like linker-regions with clustered O-glycosites, and more than half of a consecutive SEA domain (Figure 1 ) was enzymatically glycosylated in vitro with GalNAc-T3 to produce Tn-glycoform. GalNAc-T3 is expressed in OVCAR3 cell line and overexpressed in ovarian cancer compared with normal tissues (Wang et al. 2014) . Glycosylation was confirmed with reactivity with anti-Tn mAb (data not shown) and with Coomassie blue staining after NuPAGE electrophoresis ( Figure 2A ). NuPAGE mobility shift of ≈4 kDa, given the mass of GalNAc, could constitute incorporation of ≈15-20 GalNAc residues. We did not identify the actual sites of incorporation in the construct used for vaccination, but recently characterized O-glycosites in a 1.2TR MUC16 construct, which is included in the 1.7TR, expressed in CHO cells and identified 19 O-glycosites in total, resulting in 18 O-glycosites per TR (Figure 1 ) . Further, identification of actual O-glycosites in Tn-1.7TR will most likely show that many sites are not fully glycosylated and hence uninformative.
GalNAc-T3 is not expressed in CHO cells and O-glycosites and GalNAc residues incorporated may differ from that found in OVCAR3.
Humoral IgG immune response to the Tn-1.7TR MUC16 vaccine
Immunization with Tn-1.7TR MUC16 produced high IgG titers that reacted with both immunogen and unglycosylated 1.7TR protein ( Figure 2A ). Titration analysis of these proteins revealed no apparent preference of the elicited antibodies for the Tn-1.7TR MUC16 (Supplementary data, Figure S1 ). No reactivity with an irrelevant Tn-glycopeptide (Tn-MUC1 60-mer) was found indicating that IgG antibodies to the Tn-glycan hapten were not elicited in agreement with previous studies (Reis et al. 1998; Sorensen et al. 2006) . We restricted the analysis to IgG because most animals have preexisting IgM antibodies to the Tn hapten (Springer et al. 1959) .
We next performed a peptide scan of the MUC16 TR region with 17mer overlapping peptides covering the C-terminal of MUC16 1.7TR (Figure 2Ba ) to define immunodominant peptide epitopes. Two eye bleeds (EBs) were tested and both produced high titer IgG to peptides 6 and 29-30 (Figure 2Bb and S2) containing the sequences PKSPGVDR and FNTTER, respectively. One EB also reacted with peptide 1 and 19 ( Figure 2B ), while the other also reacted with peptide 2 (Supplementary data, Figure S2 ).
We further evaluated the induced IgG immune response with OVCAR3, which is highly reactive with classical MUC16 mAbs . Interestingly, the EBs did not show immunostaining with acetone-fixed OVCAR3 WT, while mAb M11 reacted strongly ( Figure 3A ) as reported previously . OVCAR3 WT has been reported to express MUC16 with more elaborate O-glycans and lesser amounts of truncated O-glycans, including Tn (Kui Wong et al. 2003; Chen et al. 2013 ). We therefore also tested OVCAR3 SimpleCells (SC), an isogenic cell line that expresses truncated O-glycans (Tn/STn) , which are positive with mAb M11, anti-Tn and STn mAbs Ricardo et al. 2014) , but the induced Abs were also negative with OVCAR3 SC ( Figure 3A ).
Generation and characterization of mAb 5E11
We generated a new mAb, 5E11, selected for reactivity with Tn-1.7TR and 1.7TR MUC16 as well as peptide 29/30. mAb 5E11 reacted with 1.7TR by western blot analysis (Figure 2A ). The binding epitope of 5E11 was further explored using C-and N-terminal truncations of MUC16 1.7TR produced in E. coli ( Figure 4A ), which showed that 5E11 reacted with fragments 1.7TR, 1.2TR, 5/2, 1/4, 5/7, K293 and, although weaker, 11/2 ( Figure 4B ). We also tested a library of short peptides where 5E11 showed reactivity with peptides 29-32 by array analysis (Figure 2Bc ). ELISA using peptides 28-36 confirmed that the epitope of this antibody resides in the overlapping sequence of peptides 29/30 ( Figure 4C ). To further define the peptide epitope, we performed an alanine-walk substitution on peptide 30 ( Figure 4D ), which showed that mutation of residues in the FNTTER motif abolished or reduced binding substantially ( Figure 4E ). The NTT sequon in this motif is N-or O-glycosylated when 1.2TR MUC16 construct is expressed in CHO SC ), and we therefore investigated the role of glycosylation in this motif for 5E11 binding.
Binding of mAb 5E11 is blocked by N-and O-glycosylation
Alignment of the FNTTER motif in the full-length MUC16 ( protein accession Q8WXI7.2) revealed that this sequence is highly conserved in MUC16. We previously determined that Asn 12,725 and Thr 12,726/ 12,727 can be glycosylated ), so we initially tested the reactivity of 5E11 with synthetic glycopeptides with an attached GlcNAc residue at the Asn or a GalNAc residue at each or both Thr residues in the KHPGSRKFNTTERVLQGL peptide ( Figure 5A ). The results showed that a single GalNAc residue at either or both Thr sites ( Figure 5B ) as well as GlcNAc at the Asn site ( Figure 5C ) completely abolished binding, suggesting that glycosylation in the FNTTER region blocks binding. Interestingly, substitution of Asn with Asp or Ala also blocked binding, suggesting that Asn is part of the binding epitope ( Figure 5D ). This implies that the use of PNGase F to remove the N-glycan in the FNTTER motif would not be expected to restore antibody binding because PNGase F treatment results in Asn>Asp conversion. We tested purified MUC16 1.2TR expressed in CHO SC and subjected to enzymatic deglycosylation with PNGase F and/or α-GalNAcase to remove N-and GalNAc O-glycans, respectively . 5E11 reacted strongly with 1.7TR expressed in E. coli, but only weakly with the 1.2TR construct expressed in CHO SC by western blot analysis ( Figure 5E ). It should be noted that the reactivity of other MUC16 mAbs tested, including 5B9 ( Figure 5E ), also appear to be relative weaker with the 1.2TR constructs compared with the E. coli 1.7TR construct , but this may not be because of glycosylation but rather due to the conformational nature of the epitope recognized by these mAbs. Pretreatment with PNGase F or αGalNAcase did not increase reactivity ( Figure 5E ).
Immunocytology with mAb 5E11 in OVCAR3
OVCAR3 WT and SC are highly positive with traditional MUC16 mAbs . We initially tested trypsinized OVCAR3 and CHO SC expressing 1.2TR MUC16 cells air-dried on slides and fixed in ice-cold acetone, and found that 5E11 did not react with OVCAR3 in striking contrast to classical MUC16 mAbs, including M11 ( Figure 3A and Supplementary data, Figure S3A ). OVCAR3 WT and SC grown directly on a cover slide and fixed with acetone or paraformaldehyde also tested negative with 5E11 (data not shown).
We therefore tested formalin-fixed and Histogel plus paraffinembedded OVCAR3 WT and SC processed similarly to histopathological specimens with antigen retrieval using a steamer. Interestingly, using this protocol, 5E11 showed comparable staining to M11 with OVCAR3 WT and SC ( Figure 3B ), and importantly without antigen retrieval of paraffin-processed cells pretreatment both 5E11 and M11 mAbs did not react (data not shown). mAb 4D8 was used as negative control. Similar results were observed with CHO SC expressing 1.2TR MUC16 (Supplementary data, Figure S3B ). Gastric cancer cell line MKN45 processed the same way stained negative with 5E11 and M11. , 6, 7, 19, 29-32. (c) Array analysis demonstrated that mAb 5E11 (1 µg/mL) had the highest reactivity with the sequence shared between peptides 29 and 31 (see also Figure 4C ).
Immunohistochemistry with mAb 5E11 in ovarian tissues
We initially tested 5E11 on unfixed frozen and paraffin-embedded tissue sections from an ovarian malignant tumor to develop an appropriate protocol (Supplementary data, Figure S4 ). However, in contrast to the analyses with OVCAR3, mAb 5E11 reacted with frozen and paraffin-embedded tissues, although with a slightly lower intensity than M11. Thus, it appears that antigen retrieval is not important with tumor tissues for exposure of the 5E11 binding epitope in contrast to cell lines. The reason for this is unclear at present. We have also assessed if antigen retrieval could affect staining for short O-glycans and no significant differences were observed, except for a higher background without antigen retrieval (data not shown). We did not have access to a comprehensive set of frozen tissue samples, so we performed an immunohistological study on paraffinembedded ovarian tumor tissues. We stained sections from cases of serous cystadenomas, serous borderline tumors and serous cystadenocarcinomas with both 5E11 and OC125 (Table I and Figure 6 ). Clinicopathologic characteristics of all cases are described in Table II . Staining revealed that all three subgroup cases were positive with 5E11 and OC125. In the majority of tissue sections, >75% of cells were stained with high intensity by both antibodies (cystadenomas: 5/7; borderline tumors: 8/8; cystadenocarcinomas: 7/9). In two borderline tumors and one cystadenocarcinoma, 5E11 showed a less intense staining compared with OC125. Only one benign tumor presented a higher percentage of positive cells with 5E11. The staining pattern of both mAbs was mainly membranous and cytoplasmic. Overall, the results showed that mAb 5E11 has broad reactivity in all subgroups analyzed comparable with OC125. We have also tested M11 and observed similar reactivity (data not shown), despite the relatively higher intensity observed in immunofluorescence (Supplementary data, Figure S4 ).
Discussion
In this study, we used an E. coli expressed MUC16 TR construct with enzymatically added Tn glycans as a vaccine to evaluate IgG immunity in mice with the overall aim to generate aberrant glycoform and cancer-specific mAbs. Contrary to our previous experience with immunization with Tn-glycopeptides (Reis et al. 1998; Sorensen et al. 2006) , we were unable to isolate Tn-MUC16 glycoform-specific mAbs, and the total serum IgG elicited showed equal reactivity with the 1.7TR protein with and without Tn glycosylation. Interestingly, the Tn-1.7TR vaccine induced antibodies to several linear epitopes in the MUC16 TR, which is in contrast to all classical MUC16 mAbs that seem to define a very stable conformational epitope in the TR SEA domain (Bressan et al. 2013; Marcos-Silva et al. 2014) . A mAb, 5E11, that reflects the IgG response to the major immunogenic epitope FNTTER was generated and shown to be dependent on lack of both N-and O-glycosylation in the minimum peptide epitope. Interestingly, 5E11 reacted well with ovarian benign and malignant tissues as well as with differentially O-glycosylated OVCAR3 cell line, suggesting that glycosylation is at least not complete in this motif in human ovarian lesions, benign or malignant. The study provides a vaccine design for MUC16 that induces IgG immunity to linear epitopes in the TR region, but further studies are clearly needed to design a vaccine construct that directs the immune response to aberrant glycoforms with cancer-specific reactivity.
We recently characterized N-and O-glycosites in the MUC16 TR expressed in CHO cells . Interestingly, O-glycans were mainly found clustered in the putative 30 aa linkerregion between the SEA domains of TRs, but isolated O-glycans were also identified in the SEA domain and in particular in the FNTTER sequence that also contains an utilized consensus N-glycosite. Although both glycosites are mutually exclusive, our mass spectrometry data suggests that the NTT sequon is more frequently N-glycosylated than non-glycosylated and to a lesser extent can be O-glycosylated. This motif was found to constitute the major immunogenic linear IgG epitope when mice were immunized with the 1.7TR construct without N-glycans. Since mAb 5E11 directed to this epitope was blocked by both N-and O-glycans in the FNTTER motif, we propose that the glycosylation of this motif is at least partially inefficient in ovarian cancer (1) with the alanine substitutions (2-10). (E) ELISA with mAb 5E11 showed strong reactivity with mutated peptides 2, 3 and 10, while peptide 5 had very weak reactivity. Peptides 4, 6, 7, 8 and 9 were unreactive. Residues "FNTTER" revealed to be more critical for binding and define the probable epitope of mAb 5E11. Peptide 1 was used as positive control. and in benign cystadenomas. This epitope does not appear to be readily available in ovarian cancer cell lines as demonstrated by the need for antigen retrieval protocols for reactivity with OVCAR3, and further studies are clearly needed to provide an explanation for this phenomenon. It is not straightforward to clarify how the epitope is exposed in cancer cell lines and tissues. First, 5E11 binding is dependent on the Asn residue in the FNTTER motif, which excludes the use of PNGase F treatment analysis of the effect of N-glycans. Secondly, we found a seemingly reciprocal relationship between N-and O-glycosylation in the FNTTER motif, but α-GalNAcase treatment did not increase 5E11 reactivity. In vitro glycosylation assays with peptide 29/30 (NLQYEEDMHHPGSRKFNTTERVLQG) showed that GalNAc-T1 and -T3 can add a GalNAc residue to this peptide and since these two isoforms are widely expressed, it is likely that the FNTTER region is O-glycosylated in most cells (Supplementary data, Figure S5 ). So far we have only identified O-glycosites in the FNTTER motif when MUC16 TR constructs were recombinantly expressed in CHO SC ). However, we could not discard that the Ser residue in the PGSRK is also glycosylated by T1 and/or T3.
The finding that mAb 5E11 required antigen retrieval to expose binding to OVCAR3 and CHO SC cell lines is unexplained. It is likely that the FNTTER motif is glycosylated in these cells in agreement with our structural analysis , in vitro enzyme analysis and the weak western blot reactivity with the MUC16 TR construct expressed in CHO SC. To our knowledge, there are no reports suggesting that antigen retrieval protocols used for paraffin sections should affect O-glycans, but this would be one explanation for the observation. The FNTTER sequon is highly conserved throughout the MUC16 TRs, but analysis of identified single-nucleotide polymorphisms (SNPs) (GenBAnk accession NM_024690.2) revealed the existence of five SNPs in this sequence (rs76265586; rs189149137; rs374167729; rs36173286; rs1872935981). However, all identified SNPs would likely destroy the binding of mAb 5E11, and it is therefore unlikely that such polymorphisms in TRs can explain how 5E11 react with frozen ovarian tissues and not cell lines expressing MUC16. Importantly, the identified SNPs were based on a transcript encoding for a protein of 14,507 aa and it is now accepted that MUC16 is composed of 22,152 aa, which suggests that additional SNPs may exist and these could lead to exposure of 5E11 epitopes without glycans. Future studies should address expression of the 5E11 epitope in normal serous epithelium in frozen and paraffin-embedded sections.
In conclusion, we provide a first design of a MUC16 TR vaccine construct that induces IgG immunity to two immunodominant linear peptide epitopes in the TR region. We produced the first MUC16 mAb with defined peptide binding motif to one of these regions, which shows similar reactivity as traditional MUC16 mAbs by immunohistology of ovarian benign and cancer lesions. Future studies are needed to further explore the epitope of this antibody and how glycosylation may affect exposure. 
Materials and methods

Production of recombinant MUC16 TR fragments in E. coli
Design and synthesis of the MUC16 expression constructs were described previously . Briefly, the MUC16 1.7TR construct was generated by PCR (nucleotides 37,978-38,770, GenBank accession XR_079401.1) and encodes for a fragment with 264 aa (spanning residues 12,660-12,923; protein accession NP_078966.2) with N-and C-terminal 6xHis tags. A series of truncated MUC16 TR constructs 1/4, 5/2, 5/7, 5/8, 5/9, 11/2 were generated by PCR from MUC16 1.7TR. MUC16 1.2TR, K292 and K293 were produced as synthetic DNA constructs, while the MUC16 F/R construct was generated by insertion of two re-annealed ssDNA oligonucleotides. All constructs were inserted into pET28 vector. Recombinant proteins were expressed in Rosetta 2(DE3) cells with IPTG induction and purified under denaturing conditions using Ni-NTA agarose (Pedersen et al. 2011 ).
In vitro enzymatic glycosylation of MUC16 1.7TR
Enzymatic O-glycosylation of purified MUC16 1.7TR expressed in E. coli to introduce GalNAc residues (Tn) was performed with GalNAc-T3 in reaction mixtures containing 100 mM sodium cacodylate buffer pH 6.5, 10 mM MnCl 2 , 0.5% Triton X-100, 4 mM UDPGalNAc, 100 mM Urea, 10 mM 2-Mercaptoethanol. Initially, GalNAc-T1 and -T3 were tested for ability to introduce GalNAc residues using NuPAGE analysis and mobility shifts to identify the best isoform (data not shown), and GalNAc-T3 was selected because it produced a large mobility shift with presumably the highest number of GalNAc residues introduced. GalNAc-T3 has been reported to be overexpressed in ovarian cancer (Wang et al. 2014) . Glycosylation was carried out at 37°C overnight (ON), and glycopeptide purified by reversed-phase chromatography. Tn-1.7TR MUC16 was separated on a NuPage Novex BisTris 4-12% gels and visualized by Coomassie blue staining.
Immunization with Tn-1.7TR MUC16
Female Balb/C mice were subcutaneously injected with 20 µg in a total volume of 200 µL (1:1 mix with Freunds adjuvant). EBs Tn-1.7TR were obtained 1 week after the third immunization and tested by immunocytochemistry, NuPAGE western blot and ELISA as described below and in Supplementary data. Three days after the fourth immunization, splenocytes and mouse myeloma cells were fused. 5E11 clone was selected based on reactivity against Tn-1.7TR by direct ELISA (data not shown) and immunohistochemistry with ovarian tumor tissues.
Production of recombinant Tn-1.2TR MUC16 in CHO SC
We previously described expression of a shorter MUC16 1.2TR construct expressed in CHO SC . Briefly, MUC16 1.2TR construct encoding for a fragment with 194 aa with a C-terminal myc tag and N-and C-terminal 6xHis tags was stably transfected into CHO SC. The CHO SC line was produced by knockout of the COSMC chaperone gene, which renders the core-1 synthase, C1GalT1, responsible for elongation of GalNAc O-glycans to the T structure, inactive . CHO SCs produce homogenous Tn glycans, but the repertoire of GalNAc-T isoforms expressed may differ from that of ovarian cancer cells and at least the GalNAc-T3 isoform is not expressed in CHO ) while this isoform is expressed in OVCAR3. Secreted protein was purified by affinity (Ni-NTA) and reversed-phase chromatography.
NuPAGE and western blot analysis
Purified recombinant MUC16 1.7TR without and with Tn glycans and N-and/or C-terminally deleted recombinant MUC16 fragments produced in E. coli were subjected to electrophoresis on NuPAGE gels. Following blotting onto nitrocellulose membranes, these were blocked in 5% BSA Tris-buffered saline plus 0.05% Tween-20 and incubated with EB Tn-1.7TR (1:3000), mAb 5E11 (1 µg/mL) and negative control mouse IgG1 (Dako) (1 µg/mL), ON at 4°C. After washing, membranes were incubated with alkaline phosphatase-conjugated antibody [anti-mouse IgG Fc-specific, 1:20,000 (Sigma)] for 1 h at room temperature (RT) and developed with 5-bromo-4-chloro-3-indolylphosphate/nitro-blue tetrazolium substrate. Release of N-and O-glycans from purified MUC16 1.2TR produced in CHO SC was performed as before . Samples were subsequently separated on Novex Tris-glycine 18% and protocol followed as described above.
Peptide-scan of the MUC16 TR
Thirty-eight 17mer peptides, with four aa offset, covering partly MUC16 TR5/TR6 were synthesized (Peptides and Elephants GmbH). Two biotinylated 25-mer peptides covering the sequences of peptides 6/7 and 29/30, respectively, were synthesized (Schaefer-N). A peptide with an Asn>Asp substitution (#30 N>D) was synthesized (NEOBiolab). An Ala walk on the peptide KHPGSRKFNTTERVLQGL was synthesized with 9 aa sequentially substituted with L-alanine, and glycopeptides with βGlcNAc or αGalNAc monosacccharides incorporated at Asn and Thr positions were chemically synthesized using Fmoc chemistry (Blixt and Clo, 2013) . 
ELISA assays
ELISA assays were performed using MaxiSorp 96-well plates (Nunc). Naked peptides were coated at 1 µg/mL and incubated ON at 4°C in carbonate-bicarbonate buffer ( pH 9.6). After blocking in PLI-P buffer [PO 4 , Na/K, 1% Triton, 1% BSA ( pH 7.4)] for 1 h at RT, plates were incubated with EB Tn-1.7TR (1:3200) for 1 h at RT. Synthetic glycopeptides were coated at 1 µg/mL and incubated ON at 4°C in carbonate-bicarbonate buffer. Asparagine substituted peptides were coated at 0.5 µg/mL and incubated as before. Plates were blocked with PLI-P buffer, followed by incubation with mAb 5E11 (1 µg/mL). Bound antibodies were detected with HRP-conjugated IgG goat anti-mouse antibody (Southern Biotech). Plates were developed with TMB+ substrate (Dako), reactions stopped with 0.5 M H 2 SO 4 and absorbance read at 450 nm.
Peptide-scan microarray print and analysis
Peptides were printed on Schott-Nexterion Slide H-MPX-16 (Schott AG) (Wandall et al. 2010; Chen et al. 2013) . Triplicates of all compounds were printed at 0.5 mg/mL in 150 mmol/L sodium phosphate ( pH 8.5) with 0.005% CHAPS. Slides were incubated with mAb 5E11 (1 µg/mL) and then detected with Cy3-conjugated goat anti-mouse IgG (H+L) (The Jackson Laboratory) diluted 1:5000. Next, slides were scanned and analyzed (Chen et al. 2013 ).
Immunocytology
Immunocytology was performed on OVCAR3 WT and SC cell lines. OVCAR3 WT expresses elongated O-glycans (Kui Wong et al. 2003) , while OVCAR3 SC is an isogenic cell line that expresses truncated O-glycans (Tn/STn) due to knockout of the COSMC gene . Trypsinized cells were seeded on slides, dried at RT and fixed for 5 min in ice-cold acetone. Next, cells were incubated ON at 4°C with EB Tn-1.7TR (1:400) or mAbs M11 (1 µg/mL) (Dako) and 5E11 (undiluted culture supernatant), followed by incubation for 1 h at RT with fluorescein isothiocyanate (FITC)-conjugated goat antimouse IgG (γ-chain specific) (Southern Biotech.). Slides were mounted in glycerol containing p-phenylenediamine and observed in a Zeiss Axioscope 2 plus AxioCam MRc.
Alternatively, OVCAR3 WT and SC cell lines were scrapped in icecold PBS and fixed in 10% neutral-buffered formalin. Then, cells were centrifuged and pellet embedded in liquefied Histogel™ (ThermoFisher Scientific). After solidification, cells were processed under a standard histology specimen protocol, embedded in a paraffin block and sectioned (3 µm). Following deparaffinization, heat-induced (98°C) antigen retrieval was performed using citrate buffer ( pH 6.0) (CE IVD, Thermo-Scientific Lab Vision). Subsequently, cells were incubated ON at 4°C with mAbs 5E11 (undiluted culture supernatant), M11 (1:60) (Neomarkers) and anti-GalNAc-T1 (mAb 4D8, IgG1) (Mandel et al. 1999 ) (undiluted culture supernatant). Incubation with secondary antibody was performed as described above and slides were mounted in vectashield mounting media. All slides were examined in a Zeiss Imager.Z1 Axio fluorescence microscope. MKN45 cell line was used as a negative control for MUC16 expression.
Immunohistochemistry
A series of ovarian tumors, including serous papillary adenocarcinomas (n = 9), serous papillary borderline adenocarcinomas (n = 8) and serous cystadenomas (n = 7), were obtained from Centro Hospitalar S. João, Porto. A pathologist (L.D.) reviewed all cases and selected a block containing representative tumor tissue for immunohistochemical studies. Formalin-fixed, paraffin-embedded tissue sections, were dewaxed, rehydrated and subjected to heat-induced antigen retrieval (98°C) using citrate buffer pH 6.0 for 30 min. Sections were blocked with 3% H 2 O 2 and incubated at RT for 1 h with mAbs 5E11 (undiluted culture supernatant) or OC125 (1:200) (Cell Marque), which has an overlapping epitope with M11 . Sections were incubated with a secondary antibody with HRP-polymer (Cytomation Envision System HRP, Dako), followed by staining with diaminobenzidinetetrahydrochloride according to the manufacturer's instructions. Slides were examined in a Zeiss optical microscope. Cases were considered positive when >10% of tumor cells were stained.
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